Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate by the advanced colorectal cancer meta-analysis project

Journal of Clinical Oncology

Volumn 10, Issue 6, 1992, Pages 896-903

  Piedbois, P ^b   Buyse, M ^a   Rustum, Y ^b   Machover, D ^b   Erlichman, C ^b   Carlson, R W ^b   Valone, F ^b   Labianca, R ^b   Doroshow, J H ^b   Petrelli, N ^b  

^a INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG MIXTURE; DRUG POTENTIATION; HUMAN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLUOROURACIL; HUMAN; LEUCOVORIN; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; SUPPORT, NON-U.S. GOV'T; SURVIVAL RATE;

EID: 0026721532     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1992.10.6.896     Document Type: Article

References (29)

1. Berger SH, Hakala MT: Relationship of dUMP and free FdUMP pools to inhibition of thymidilate synthetase by 5-fluorouracil. Mol Pharmacol 25:303-309, 1984
2. Evans RM, Laskin JD, Hakala MT: Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41:3288-3295, 1981
3. Waxman S, Bruckner H: The enhancement of 5-fluorouracil antimetabolic activity by leucovorin. menadione and alphatocopherol. Eur J Cancer Clin Oncol 18:685-692, 1982
4. Machover D, Goldschmidt E. Chollet P. et al: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4:685-696, 1986
5. Machover D, Schwartzenberg L, Goldschmidt E, et al: Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: A pilot study. Cancer Treat Rep 66:1803-1807, 1982
6. Madajewicz S, Petrelli N. Rustum YM, et al: Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res 44:4667-4669, 1984
7. Doroshow JH, Multhauf P, Leong L, et al: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8:491-501, 1990
8. Erlichman C, Fine S, Wong A, et al: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469-475, 1988
9. Petrelli N, Douglass HO, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 7:1419-1426, 1989
10. Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987
11. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1418, 1989
12. Valone FH, Friedman MA, Wittlinger PS, et al: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: A randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427-1436, 1989
13. O'Connell M, Poon M, Wieand H, et al: Biochemical modulation of 5-fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in the treatment of advanced colorectal cancer. Proc Am Soc Clin Oncol 9:408, 1990 (abstr)
14. Gerstner J, O'Connell MJ, Wieand HS, et al: A prospectively randomized clinical trial comparing 5FU combined with either high or low dose leucovorin for the treatment of advanced colorectal cancer. Proc Am Soc Clin Oncol 10:404, 1991 (abstr)
15. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
16. Cricca A, Martoni A, Guaraldi M. et al: Randomized clinical trial of 5-FU + folinic acid vs 5-FU in advanced gastrointestinal cancers. Proc ESMO 13:427, 1988
17. Nobile MT, Vidili MG, Sobrero A, et al: 5-fluorouracil alone or combined with high-dose folinic acid in advanced colorectal cancer patients. Proc Am Soc Clin Oncol 7:371, 1988 (abstr)
18. Di Costanzo F, Bartolucci R, Sofra M, et al: 5-fluorouracil alone vs high dose folinic acid and 5-FU in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Proc Am Soc Clin Oncol 8:410, 1989 (abstr)
19. Labianca R, Pancera G, Aitini E, et al: Folinic acid + 5-fluorouracil (5FU) versus equidose 5FU in advanced colorectal cancer. Phase III study of "GISCAD" (Italian Group for the Study of Digestive Tract Cancer). Ann Oncol 2:673-679, 1991
20. Mantel H, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
21. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. (II. Analysis and examples). Br J Cancer 35:1-39, 1977
22. Early breast cancer trialists' collaborative group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. New Engl J Med 319:1681-1692, 1988
23. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statistical Assoc 53:457-481, 1958
24. Cox DR: The Analysis of Binary Data. London, England, Methuen, 1970
25. Cox DR: Regression models and life tables (with discussion). J R Stat Soc (Br) 34:187-220, 1972
26. Ovarian Cancer Meta-Analysis Project: Cyclophosphamide plus cisplatin versus Cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Oncol 9:1668-1674, 1991
27. Buyse M, Ryan L: Issues of efficiency in combining proportions of deaths from several clinical trials. Stat Med 6:565-576, 1987
28. Machover D: Potentiation of the antitumor activity of the fluoropyrimidines by leucovorin: Rationale and clinical data, in Pinedo HM, Rustum YM (eds): Leucovorin Modulation of Fluoro-Pyrimidines: A New Frontier in Cancer Chemotherapy. London, UK, Royal Society of Medicine Services, 1989, pp 1-9
29. Prentice RL: Surrogate endpoints in clinical trials. Definitions and operational criteria. Stat Med 8:431-440, 1989